Abilify (aripiprazole) is a prescription drug used to treat mood disorders such as schizophrenia. Learn about side effects, warnings, dosage, and more. Cognitive-behavioral therapy: This looks into any negative thought patterns you may have and challenges them in order to change your behavior. Interpersonal and social rhythm therapy: This aims to improve disruptions to your biological or social rhythms (such as sleep disturbances and relationship issues). Family focused therapy: This involves your family in your treatment, educating them and. Negative symptoms, including lack of emotion, decreased joy or motivation, delayed speech, and difficulty beginning and sustaining activities,   can be scary and extremely debilitating. If you or someone you love is struggling with negative symptoms, you may need help in order to complete daily tasks. Further, the non-inferiority of Abilify Maintena compared to oral aripiprazole 10-30 mg is supported by the results of the analysis of the Positive and Negative Syndrome Scale score (PANSS). Table 1 PANSS Total Score – Change From Baseline to Week 38-LOCF: Randomised Efficacy Sample a, b Poor hygiene can be a sign of self-neglect, which is the inability or unwillingness to attend to one's personal needs.Poor hygiene often accompanies certain mental or emotional disorders, including severe depression and psychotic disorders. Dementia is another common cause of poor hygiene. Other people may develop poor hygiene habits due to social factors such as poverty or inadequacy of. Medication is an essential component of treating schizophrenia. Medication can help relieve symptoms of schizophrenia such as delusions, hallucinations, and disorganized thinking by blocking certain chemical receptors in the brain. The most commonly prescribed types of medications for schizophrenia are antipsychotics, and there are two classifications of antipsychotics, typical and atypical. Abilify did result in a significantly greater improvement in the PANSS negative subscores at weeks 26 and 52 and the MADRS total score at weeks 8, 26 and 52. [Mean change PANSS negative subscale score (week 26: p = 0.029; 95% CI: -1.52, -0.08) (week 52: p = 0.011; 95% CI: -1.73, -0.23). Mean change MADRS total score (week 8: p = 0.027; 95% CI: -1.74, -0.11) (week 26: p = 0.22; 95% CI: -1.95. ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). ABILIFY is not approved for the treatment of patients with dementia-related psychosis. Efficacy was evaluated using the total score on the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30 item scale that measures positive symptoms of schizophrenia (7 items), negative symptoms of schizophrenia (7 items), and general psychopathology (16 items), each rated on a scale of 1. Abilify (Aripiprazole) is an atypical antipsychotic medication that is used to treat schizophrenia, bipolar disorder, and in some cases is used as an “add on” treatment in severe depression. If you are on Abilify and are switching to another medication and/or planning on withdrawing from it, you should always work with a psychiatrist.